PI3K Inhibitors in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Patient Selection and Biomarker Testing
- The American Society of Clinical Oncology recommends PIK3CA mutation testing before considering alpelisib therapy for patients with HR-positive, HER2-negative advanced breast cancer, using next-generation sequencing on either tumor tissue or circulating tumor DNA in plasma 1, 2
- The European Society for Medical Oncology suggests that if circulating tumor DNA testing is negative, reflex to tumor tissue testing is necessary, as plasma testing misses approximately 44% of mutations confirmed in tissue 1, 3
- The National Comprehensive Cancer Network recommends testing the most recent tumor sample available, as PIK3CA mutations can be acquired during metastatic treatment 4, 5
- Specific activating mutations in exons 9 and 20 form the basis of regulatory approval for alpelisib therapy 4
Treatment Sequencing
- The American College of Physicians recommends alpelisib plus fulvestrant as a treatment option for patients with PIK3CA-mutated advanced breast cancer after progression on prior endocrine therapy, specifically positioning it after CDK4/6 inhibitor failure rather than as first-line therapy 6, 2
- The European Society for Medical Oncology suggests that alpelisib should be used after CDK4/6 inhibitor therapy, not before, given the superior benefit profile of CDK4/6 inhibitors 6, 7
Efficacy Data
- The SOLAR-1 trial demonstrated a progression-free survival of 11.0 months with alpelisib-fulvestrant versus 5.7 months with placebo-fulvestrant in PIK3CA-mutated cohort, with a hazard ratio of 0.65 (P<0.001) 6
- The overall survival was 39.3 months versus 31.4 months, but did not meet prespecified statistical significance 1, 2, 3
Critical Patient Selection Criteria
- The American Diabetes Association recommends careful screening for contraindications, such as pre-existing diabetes or elevated baseline HbA1c, before initiating alpelisib therapy 6, 7
- The American Heart Association suggests that significant comorbidities that would compromise toxicity management should be excluded before initiating alpelisib therapy 6
Toxicity Management
- The National Comprehensive Cancer Network recommends starting non-sedating antihistamines prophylactically at treatment initiation to prevent rash, and discontinuing after 4 weeks as rash risk is highest in first 2 weeks 6, 7
- The European Society for Medical Oncology suggests that close monitoring of glucose levels is mandatory, and dose reductions/interruptions should be considered in approximately 70% of patients 6, 7
Quality of Life Considerations
- The American Society of Clinical Oncology reports that despite significant toxicity, quality of life data from SOLAR-1 showed no overall deterioration in Global Health Status/QoL scores between alpelisib and placebo arms 2
Inavolisib Use in PIK3CA‑Mutated HR‑Positive Metastatic Breast Cancer – Evidence‑Based Recommendations
Patient Selection Criteria
Diagnostic Testing Considerations
Treatment Positioning and Guideline Recommendations
Safety Monitoring and Management
Quality‑of‑Life Outcomes
Management of PIK3CA‑Mutated HR⁺/HER2‑Negative Metastatic Breast Cancer
Biomarker Testing
- PIK3CA mutation testing must be performed before starting a PI3K inhibitor, using next‑generation sequencing of circulating tumor DNA (ctDNA) from plasma as the preferred rapid, non‑invasive first‑line method; if plasma testing is negative, reflex testing of tumor tissue is required to avoid false‑negative results 11, 12.
First‑Line Therapy
- For treatment‑naïve patients, the recommended first‑line regimen is an aromatase inhibitor combined with a CDK4/6 inhibitor (based on phase III trial data) 13, 11.
Post‑Progression Therapy
- In patients who have progressed after endocrine therapy with or without a CDK4/6 inhibitor, alpelisib 300 mg daily plus fulvestrant 500 mg (administered every 28 days with an additional dose on day 15 of cycle 1) should be used as the standard treatment option (phase III evidence) 11, 12.